miR-770-5p-induced cellular switch to sensitize trastuzumab resistant breast cancer cells targeting HER2/EGFR/IGF1R bidirectional crosstalk.

Turkish journal of biology = Turk biyoloji dergisi Pub Date : 2024-02-05 eCollection Date: 2024-01-01 DOI:10.55730/1300-0152.2690
Senem Noyan, Bala Gür Dedeoğlu
{"title":"miR-770-5p-induced cellular switch to sensitize trastuzumab resistant breast cancer cells targeting HER2/EGFR/IGF1R bidirectional crosstalk.","authors":"Senem Noyan, Bala Gür Dedeoğlu","doi":"10.55730/1300-0152.2690","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Studies highlighted the bidirectional crosstalk between the HER family members in breast cancer as resistance mechanism to anti-HER agents. Cross-signaling between HER2/EGFR and ER/IGF1R could play role in the development of resistance to therapeutics hence stimulating cell growth. To overcome this resistance, combined therapies targeting both pathways simultaneously have been proposed as an effective strategy. The involvement of miRNAs in resistance of targeted therapies like trastuzumab was demonstrated in recent studies. Hence the regulation of miRNAs in resistance state could reverse the cell behaviour to drugs. Previously we found that overexpression of miR-770-5p downregulated AKT and ERK expression through HER2 signaling and potentiated the effect of trastuzumab. In this study we examined the impact of miR-770-5p on trastuzumab resistance.</p><p><strong>Materials and methods: </strong>Cells were treated with tamoxifen or trastuzumab to examine their role in bidirectional crosstalk. The molecule mechanism of miR-770-5p on HER2/EGFR/IGF1R bidirectional crosstalk was explored by western blot. The expression of miR-770-5p in trastuzumab resistant cells was examined by q-PCR. To investigate the effect of miR-770-5p on cancer cell proliferation in trastuzumab resistance state, resistant cells were analyzed by iCELLigence real-time cell analyzer.</p><p><strong>Results: </strong>miR-770-5p expression was significantly downregulated in trastuzumab-resistant BT-474 and SK-BR-3 cells. Overexpression of miR-770-5p sensitized the resistant cells to trastuzumab, as evidenced by reduced cell proliferation and increased cell viability. Additionally, in resistant cells, increased expression and activation of EGFR and IGF1R were observed. However, miR-770-5p overexpression resulted in decreased phosphorylation of AKT and ERK, indicating its suppressive role in EGFR/HER2 signaling. Furthermore, miR-770-5p downregulated the expression of IGF1R and mTOR, suggesting its involvement in regulating the escape signaling mediated by IGF1R in resistance.</p><p><strong>Conclusion: </strong>In conclusion, our findings demonstrate the critical role of miR-770-5p in regulating bidirectional crosstalk and overcoming trastuzumab resistance in breast cancer cells. These results highlight the potential of miR-770-5p as a therapeutic target to improve the efficacy of targeted therapies and address resistance mechanisms in breast cancer.</p>","PeriodicalId":94363,"journal":{"name":"Turkish journal of biology = Turk biyoloji dergisi","volume":"48 2","pages":"153-162"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265924/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish journal of biology = Turk biyoloji dergisi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55730/1300-0152.2690","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aim: Studies highlighted the bidirectional crosstalk between the HER family members in breast cancer as resistance mechanism to anti-HER agents. Cross-signaling between HER2/EGFR and ER/IGF1R could play role in the development of resistance to therapeutics hence stimulating cell growth. To overcome this resistance, combined therapies targeting both pathways simultaneously have been proposed as an effective strategy. The involvement of miRNAs in resistance of targeted therapies like trastuzumab was demonstrated in recent studies. Hence the regulation of miRNAs in resistance state could reverse the cell behaviour to drugs. Previously we found that overexpression of miR-770-5p downregulated AKT and ERK expression through HER2 signaling and potentiated the effect of trastuzumab. In this study we examined the impact of miR-770-5p on trastuzumab resistance.

Materials and methods: Cells were treated with tamoxifen or trastuzumab to examine their role in bidirectional crosstalk. The molecule mechanism of miR-770-5p on HER2/EGFR/IGF1R bidirectional crosstalk was explored by western blot. The expression of miR-770-5p in trastuzumab resistant cells was examined by q-PCR. To investigate the effect of miR-770-5p on cancer cell proliferation in trastuzumab resistance state, resistant cells were analyzed by iCELLigence real-time cell analyzer.

Results: miR-770-5p expression was significantly downregulated in trastuzumab-resistant BT-474 and SK-BR-3 cells. Overexpression of miR-770-5p sensitized the resistant cells to trastuzumab, as evidenced by reduced cell proliferation and increased cell viability. Additionally, in resistant cells, increased expression and activation of EGFR and IGF1R were observed. However, miR-770-5p overexpression resulted in decreased phosphorylation of AKT and ERK, indicating its suppressive role in EGFR/HER2 signaling. Furthermore, miR-770-5p downregulated the expression of IGF1R and mTOR, suggesting its involvement in regulating the escape signaling mediated by IGF1R in resistance.

Conclusion: In conclusion, our findings demonstrate the critical role of miR-770-5p in regulating bidirectional crosstalk and overcoming trastuzumab resistance in breast cancer cells. These results highlight the potential of miR-770-5p as a therapeutic target to improve the efficacy of targeted therapies and address resistance mechanisms in breast cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对 HER2/EGFR/IGF1R 双向串扰,miR-770-5p 诱导细胞转换,以增敏曲妥珠单抗耐药的乳腺癌细胞。
背景/目的:研究强调,乳腺癌中 HER 家族成员之间的双向串扰是抗 HER 药物的耐药机制。HER2/EGFR和ER/IGF1R之间的交叉信号传递可能会导致治疗药物的抗药性,从而刺激细胞生长。为了克服这种耐药性,有人提出了同时针对这两种途径的联合疗法,认为这是一种有效的策略。最近的研究表明,miRNAs 参与了曲妥珠单抗等靶向疗法的耐药性。因此,在耐药状态下调控 miRNA 可逆转细胞对药物的行为。此前我们发现,miR-770-5p的过表达会通过HER2信号传导下调AKT和ERK的表达,并增强曲妥珠单抗的作用。本研究探讨了 miR-770-5p 对曲妥珠单抗耐药性的影响:用他莫昔芬或曲妥珠单抗处理细胞,研究它们在双向串扰中的作用。通过 Western 印迹探讨了 miR-770-5p 在 HER2/EGFR/IGF1R 双向串扰中的分子机制。通过q-PCR检测了miR-770-5p在曲妥珠单抗耐药细胞中的表达。结果:miR-770-5p在曲妥珠单抗耐药的BT-474和SK-BR-3细胞中表达显著下调。miR-770-5p的过表达使耐药细胞对曲妥珠单抗敏感,表现为细胞增殖减少和细胞活力增加。此外,在耐药细胞中还观察到表皮生长因子受体和 IGF1R 的表达和活化增加。然而,miR-770-5p 过表达导致 AKT 和 ERK 磷酸化减少,表明它在表皮生长因子受体/HER2 信号转导中起抑制作用。此外,miR-770-5p 下调了 IGF1R 和 mTOR 的表达,表明它参与调节了抗药性中由 IGF1R 介导的逃逸信号转导:总之,我们的研究结果表明,miR-770-5p 在调节双向串扰和克服乳腺癌细胞对曲妥珠单抗的耐药性方面起着关键作用。这些结果凸显了 miR-770-5p 作为治疗靶点的潜力,可提高靶向疗法的疗效并解决乳腺癌的耐药机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Antimetastatic effect of nanodiamond-conjugated quercetin against colon cancer: an in vivo study. Disappearance of Cdc14 from the daughter spindle pole body requires Glc7-Bud14. Delivery of BikDD proapoptotic gene in Peptide-18-targeted Poly(2-oxazoline)-DOPE nanoliposomes for breast cancer models. Pterostilbene suppresses head and neck cancer cell proliferation via induction of apoptosis. Optical imaging and gene transfection potential of linear polyethylenimine-coated Ag2S near-infrared quantum dots.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1